John T Cavan - Net Worth and Insider Trading
John T Cavan Net Worth
The estimated net worth of John T Cavan is at least $16,280 dollars as of 2024-06-10. John T Cavan is the CFO of Hepion Pharmaceuticals Inc and owns about 14,800 shares of Hepion Pharmaceuticals Inc (HEPA) stock worth over $16,280. Details can be seen in John T Cavan's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John T Cavan has not made any transactions after 2021-02-18 and currently still holds the listed stock(s).
Transaction Summary of John T Cavan
John T Cavan Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John T Cavan owns 2 companies in total, including Hepion Pharmaceuticals Inc (HEPA) , and Aegerion Pharmaceuticals Inc (AEGR) .
Click here to see the complete history of John T Cavan’s form 4 insider trades.
Insider Ownership Summary of John T Cavan
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HEPA | Hepion Pharmaceuticals Inc | 2021-02-18 | Chief Financial Officer |
| AEGR | Aegerion Pharmaceuticals Inc | 2010-10-21 | VP & Chief Accounting Officer |
John T Cavan Latest Holdings Summary
John T Cavan currently owns a total of 1 stock. John T Cavan owns 14,800 shares of Hepion Pharmaceuticals Inc (HEPA) as of February 18, 2021, with a value of $16,280.
Latest Holdings of John T Cavan
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals Inc | 2021-02-18 | 14,800 | 1.10 | 16,280 |
Holding Weightings of John T Cavan
John T Cavan Form 4 Trading Tracker
According to the SEC Form 4 filings, John T Cavan has made a total of 2 transactions in Hepion Pharmaceuticals Inc (HEPA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Hepion Pharmaceuticals Inc is the acquisition of 10,000 shares on February 18, 2021, which cost John T Cavan around $20,000.
Insider Trading History of John T Cavan
- 1
John T Cavan Trading Performance
GuruFocus tracks the stock performance after each of John T Cavan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John T Cavan is -7.98%. GuruFocus also compares John T Cavan's trading performance to market benchmark return within the same time period. The performance of stocks bought by John T Cavan within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John T Cavan's insider trading performs compared to the benchmark.
Performance of John T Cavan
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 7.61 | | | | | |
| Relative Return to S&P 500(%) | 6.42 | | | | | |
John T Cavan Ownership Network
John T Cavan Owned Company Details
What does Hepion Pharmaceuticals Inc do?
Who are the key executives at Hepion Pharmaceuticals Inc?
John T Cavan is the Chief Financial Officer of Hepion Pharmaceuticals Inc. Other key executives at Hepion Pharmaceuticals Inc include Chief Scientific Officer Robert T Foster , director & CEO and President Gary S Jacob , and 10 percent owner Donald E Garlikov .
Hepion Pharmaceuticals Inc (HEPA) Insider Trades Summary
Over the past 18 months, John T Cavan made no insider transaction in Hepion Pharmaceuticals Inc (HEPA). Other recent insider transactions involving Hepion Pharmaceuticals Inc (HEPA) include a net purchase of 8,000 shares made by Peter Wijngaard , and a net purchase of 3,200 shares made by Robert T Foster .
In summary, during the past 3 months, insiders sold 0 shares of Hepion Pharmaceuticals Inc (HEPA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Hepion Pharmaceuticals Inc (HEPA) were sold and 11,200 shares were bought by its insiders, resulting in a net purchase of 11,200 shares.
Hepion Pharmaceuticals Inc (HEPA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Hepion Pharmaceuticals Inc Insider Transactions
John T Cavan Mailing Address
Above is the net worth, insider trading, and ownership report for John T Cavan. You might contact John T Cavan via mailing address: C/o Stemline Therapeutics, Inc., 750 Lexington Avenue, 6th Floor, New York Ny 10022.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
